Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752157 | 0.89 | DRD4 (0.51) | HCRTR2MEN1KMT2ALMNAHCRTR1 | |
| SCHEMBL752408 | 0.89 | DRD4 (0.42) | HCRTR2MEN1KMT2ALMNALDHA | |
| SCHEMBL752520 | 0.89 | HCRTR2 (0.44) | HCRTR2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL755460 | 0.88 | HCRTR2 (0.43) | HCRTR2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL752716 | 0.87 | HCRTR2 (0.47) | HCRTR2KMT2AALDH1A1LMNAHCRTR1 | |
| SCHEMBL752226 | 0.85 | HCRTR2 (0.53) | HCRTR2MEN1KMT2AHCRTR1DRD4 | |
| SCHEMBL750883 | 0.85 | HCRTR2 (0.41) | HCRTR2LMNALDHAHCRTR1MAPT | |
| SCHEMBL752250 | 0.84 | HCRTR2 (0.49) | HCRTR2MEN1KMT2ALMNAHCRTR1 | |
| SCHEMBL754100 | 0.83 | HCRTR2 (0.45) | HCRTR2MEN1KMT2AHCRTR1NPSR1 | |
| SCHEMBL751790 | 0.83 | HCRTR2 (0.64) | HCRTR2HCRTR1MAPTSMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | claimed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | claimed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | claimed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | claimed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | claimed |
| EP-2430004-B1 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2430004-A2 | NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | HCRTR2, HCRTR1, NPY4R | HCRTR2 1/4885MEN1 949/4885KMT2A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.